X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GSK PHARMA VENUS REMEDIES/
GSK PHARMA
 
P/E (TTM) x -711.4 63.8 - View Chart
P/BV x 0.2 10.3 2.0% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 VENUS REMEDIES   GSK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
GSK PHARMA
Mar-17
VENUS REMEDIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2183,838 5.7%   
Low Rs822,637 3.1%   
Sales per share (Unadj.) Rs365.6354.2 103.2%  
Earnings per share (Unadj.) Rs1.539.8 3.7%  
Cash flow per share (Unadj.) Rs37.942.9 88.5%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs382.5236.9 161.5%  
Shares outstanding (eoy) m11.4484.70 13.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.49.1 4.5%   
Avg P/E ratio x101.081.4 124.0%  
P/CF ratio (eoy) x4.075.5 5.2%  
Price / Book Value ratio x0.413.7 2.9%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m1,717274,216 0.6%   
No. of employees `0001.04.7 21.7%   
Total wages/salary Rs m3244,830 6.7%   
Avg. sales/employee Rs Th4,100.76,387.0 64.2%   
Avg. wages/employee Rs Th318.01,028.3 30.9%   
Avg. net profit/employee Rs Th16.7717.1 2.3%   
INCOME DATA
Net Sales Rs m4,18330,000 13.9%  
Other income Rs m20728 2.8%   
Total revenues Rs m4,20330,728 13.7%   
Gross profit Rs m8124,190 19.4%  
Depreciation Rs m417263 158.5%   
Interest Rs m3800-   
Profit before tax Rs m354,655 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m181,744 1.0%   
Profit after tax Rs m173,368 0.5%  
Gross profit margin %19.414.0 138.9%  
Effective tax rate %51.637.5 137.6%   
Net profit margin %0.411.2 3.6%  
BALANCE SHEET DATA
Current assets Rs m2,77116,742 16.5%   
Current liabilities Rs m1,9317,202 26.8%   
Net working cap to sales %20.131.8 63.1%  
Current ratio x1.42.3 61.7%  
Inventory Days Days12552 241.4%  
Debtors Days Days5421 258.6%  
Net fixed assets Rs m5,3288,635 61.7%   
Share capital Rs m114847 13.5%   
"Free" reserves Rs m4,17719,222 21.7%   
Net worth Rs m4,37620,069 21.8%   
Long term debt Rs m1,91110 19,105.0%   
Total assets Rs m8,42830,038 28.1%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40 87,611.7%  
Sales to assets ratio x0.51.0 49.7%   
Return on assets %4.711.2 42.0%  
Return on equity %0.416.8 2.3%  
Return on capital %6.625.5 25.9%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m0528 0.0%   
Fx outflow Rs m8587,193 11.9%   
Net fx Rs m-858-6,665 12.9%   
CASH FLOW
From Operations Rs m4692,360 19.9%  
From Investments Rs m293,008 1.0%  
From Financial Activity Rs m-464-5,108 9.1%  
Net Cashflow Rs m35260 13.3%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 1.8%  
FIIs % 0.6 23.8 2.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 102,036 19.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS